Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Rebel fighter training

Training new recruits to Congo's M23 insurgent group.  Slideshow 

Photo

Running while blind

Blind or visually impaired students compete in blind track and field tournament.  Slideshow 

Sponsored Links

Sex hormone explains higher liver cancer risk in men

Related Topics

HONG KONG | Wed May 19, 2010 4:07am EDT

HONG KONG (Reuters) - Male sex hormones may explain why men who suffer from the hepatitis B liver disease are more likely to develop liver cancer than women, researchers in Taiwan have found.

In a paper published in the journal Science on Wednesday, the researchers said hepatitis B viruses attach themselves to receptors of the male sex hormone androgen before going on to damage liver tissue and cause cancer.

"The findings indicate that using drugs to destroy ... androgen receptors could be a new way to battle liver cancer at an early stage," they wrote.

Liver cancer is the fifth most common cancer and the third leading cause of global cancer death.

Hepatitis B virus infection, which is endemic in many Asian countries including China, is a leading cause of liver cancer and accounts for half of liver cancer cases worldwide.

Men are up to seven times more likely than women to develop liver cancer. Among hepatitis B virus carriers, men are up to three times more likely to develop liver cancer than women.

Led by Ming-Heng Wu at the Institute of Basic Medical Sciences in National Cheng Kung University in Tainan, Taiwan, researchers found that hepatitis B viruses have a special DNA sequence which draws it to androgen receptors.

"The androgen receptors in liver cells bind to this sequence and trigger a cascade of damage to liver tissue," they explained.

In their experiment, the researchers created mice that were infected with the hepatitis B virus and could easily develop liver tumors upon exposure to cancer-causing agents.

Some of these were genetically modified to be lacking in androgen receptors in their livers.

By week 22 in the experiment, more than 90 percent of those mice with androgen receptors had developed liver tumors compared to 27 percent of the mice without androgen receptors.

Tinkering with the receptors did not change overall androgen levels or leave any obvious toxic effects in the mice.

"Targeting the androgen receptor rather an androgen could be a promising therapy for liver cancer," the researchers said.

(Reporting by Tan Ee Lyn, editing by Miral Fahmy)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
dandelay wrote:
I take testosterone injections and am HepB+, currently undetectable thru a drug regimen in conjunction with my HIV+ status. Should I worry about liver cancer due to this combination?

May 19, 2010 1:08pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.